[ET Net News Agency, 13 July 2026] Macquarie raised the target price for BeOne Medicines (06160) to HKD257 from HKD244 and maintained the "outperform" rating.
The research house said it expects BeOne to achieve OPM of 13% in 2026. (rc)
The research house said it expects BeOne to achieve OPM of 13% in 2026. (rc)